Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background And Purpose: Parkinson's disease (PD) with glucocerebrosidase (GBA) gene mutation (GBA-PD) is known to show more rapid clinical progression than sporadic PD without GBA mutation (sPD). This study was performed to delineate the specific patterns of cortical hypoperfusion, dopamine transporter uptake and cardiac meta-iodobenzylguanidine (MIBG) uptake of GBA-PD in comparison to sPD.
Methods: Through next-generation sequencing analysis targeting 41 genes, a total of 16 GBA-PD and 24 sPD patients (sex, age matched) were enrolled in the study, and the clinical, dual-phase [ F]-N-(3-fluoropropyl)-2β-carboxymethoxy-3β-(4-iodophenyl) nortropane ( F-FP-CIT) positron emission tomography (PET) and cardiac I-MIBG scintigraphy results were compared between the two groups.
Results: The GBA-PD group had higher rates of rapid eye movement sleep behavior disorder, orthostatic hypotension and neuropsychiatric symptoms than the sPD group. Early-phase F-FP-CIT PET showed significantly lower standard uptake value ratio on bilateral posterior parietal cortex (0.94 ± 0.05 vs. 1.02 ± 0.04, p = 0.011) and part of the occipital cortex (p < 0.05) in the GBA-PD group than the sPD group. In striatal dopamine transporter uptake, the regional standard uptake value ratio, asymmetry index and caudate-to-putamen ratio were similar between the two groups. The GBA-PD group had a lower heart-to-mediastinum uptake ratio in I-MIBG scintigraphy than the sPD group.
Conclusions: The GBA-PD patients showed decreased regional perfusion in the bilateral posterior parietal and occipital cortex. Cardiac sympathetic denervation and non-motor symptoms (orthostatic hypotension, rapid eye movement sleep behavior disorder) were more common in GBA-PD than sPD. These findings suggest that GBA-PD patients have more widespread peripheral (extranigral) α-synuclein accumulation, representing a body-first PD subtype.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ene.15615 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Role of Quantification Values in the Visual Interpretation of Dopamine Transporter PET Images.
Clin Nucl Med
August 2025
Department of Nuclear Medicine and Molecular Imaging.
Background: This study aimed to identify the quantified uptake values that can aid the visual interpretation of dopamine transporter (DAT) PET images.
Patients And Methods: A total of 155 patients (82 men, 73 women; mean age 67.7 y) who underwent [ 18 F]-N-(3-fluoropropyl)-2β-carboxymethoxy-3β-(4-iodophenyl) nortropane ( 18 F-FP-CIT) PET scans for suspected Parkinson disease were included.
Association Between Dopamine Transporter Activity in the Striatum on 18 F-FP-CIT PET and Overall Survival of Patients With Parkinsonism.
Clin Nucl Med
October 2025
Division of Nuclear Medicine, Department of Radiology, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Purpose: To investigate whether the overall survival (OS) of patients with parkinsonism is associated with dopamine transporter activity in the striatum measured by 18 F-N-(3-fluoropropyl)-2β-carbon ethoxy-3β-(4-iodophenyl) nortropane positron emission tomography ( 18 F-FP-CIT PET).
Methods: From March 2021 to December 2021, 18 F-FP-CIT PET images from patients with Parkinsonism were retrospectively reviewed. Dopamine transporter activity in each striatal region was automatically measured as striatal binding ratio (BR) from PET DICOM files using AI-based quantification (BTXBrain, v1.
Combining Dopamine Transporter and Amyloid PET Tracer: A Preclinical Study on Dual-Target Imaging.
Mol Imaging Biol
August 2025
Department of Nuclear Medicine and Molecular Imaging, School of Medicine, Ajou University, 206, World cup-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do, Suwon, 16499, Korea.
Purpose: This study aimed to evaluate the feasibility and diagnostic utility of a dual-target positron emission tomography (PET) imaging approach using a cocktail of N-3-[F]fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl) nortropane ([F]FP-CIT) and [F]florbetaben (FBB) for the simultaneous assessment of dopaminergic and amyloid changes in a preclinical setting.
Procedures: We utilized both Parkinson's disease (PD) and Alzheimer's disease (AD) mouse models, as well as a control group, to investigate the uptake of [F]FP-CIT and [F]FBB individually and in combination. PET imaging was conducted, and standardized uptake value ratios (SUVRs) were analyzed for each model across the striatal and cortical regions.
A Head-to-Head Comparison of 18 F-FP-CIT and 18 F-FDOPA PET/CT in Early Parkinson Disease.
Clin Nucl Med
September 2025
Department of Neurology, College of Medicine, The Catholic University of Korea.
Purpose: To compare the diagnostic performance between 18 F-N-3-fluoropropyl-2beta-carbon ethoxy-3beta-4-iodophenyl nortropane ( 18 F-FP-CIT) and 6- 18 F-fluoro-L-dopa ( 18 F-FDOPA) PET/CT in patients with early Parkinson disease (PD).
Methods: This study included 42 de novo PD patients who were clinically diagnosed at a university-affiliated tertiary hospital in South Korea and underwent 18 F-FP-CIT and 18 F-FDOPA PET imaging from November 2019 and March 2024. 18 F-FP-CIT and 18 F-FDOPA PET CT images were assessed at the initial diagnosis.
GAN-based Denoising for Scan Time Reduction and Motion Correction of 18 F FP-CIT PET/CT: A Multicenter External Validation Study.
Clin Nucl Med
October 2025
Department of Nuclear Medicine, Yonsei University College of Medicine.
Purpose: AI-driven scan time reduction is rapidly transforming medical imaging with benefits such as improved patient comfort and enhanced efficiency. A Dual Contrastive Learning Generative Adversarial Network (DCLGAN) was developed to predict full-time PET scans from shorter, noisier scans, improving challenges in imaging patients with movement disorders.
Patients And Methods: 18 F FP-CIT PET/CT data from 391 patients with suspected Parkinsonism were used [250 training/validation, 141 testing (hospital A)].